Updates in Essential Tremor Care
Episode 68, Jul 15, 2022, 10:00 AM
Welcome to the NeurologyLive® Mind Moments™ podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, we spoke with Rajesh Pahwa, MD, professor of neurology, and director, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center. He spoke about the current state of treatment for essential tremor, including the therapeutic and surgical options for this population, and shared his perspective on the latest advances in clinical care and diagnosis, the role of the patient-physician relationship, and the research into the disease's underlying processes.
In this episode, we spoke with Rajesh Pahwa, MD, professor of neurology, and director, Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center. He spoke about the current state of treatment for essential tremor, including the therapeutic and surgical options for this population, and shared his perspective on the latest advances in clinical care and diagnosis, the role of the patient-physician relationship, and the research into the disease's underlying processes.
Episode Breakdown:
- 1:25 – Overview of the current state of essential tremor care
- 7:05 – Changes in thinking about essential tremor
- 9:05 – Potential in the therapeutics pipeline
- 10:45 – Advances in the understanding of essential tremor
- 12:40 – Neurology News Minute
- 15:30 – The role of shared decision-making in care
- 18:50 – Surgical options for essential tremor treatment
- 22:00 – Education and diagnosis outside of movement specialists
- 24:00 – Advances on the horizon
Check out Medical World News' Second Opinion only at medicalworldnews.com
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Biogen, Alectos Announce Licensing Agreement for Parkinson Disease GBA2 Inhibitor AL01811
- FDA Advisory Committee Agrees to Reconvene for Decision on ALS Treatment AMX0035
- FDA Accepts BLA for Lecanemab in Alzheimer Disease, Sets PDUFA Date for January 2023
- FDA Places Clinical Hold on Phase 2/3 ReMEDy2 Trial of DM199 in Acute Ischemic Stroke
Thanks for listening to the NeurologyLive® Mind Moments™ podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.